Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Myocardial Infarction

Why this status

  1. 13 Oct 2026: Trial registered, NCT07872046

The trials

NCT07872046: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors

State
Not started
Phase
Phase 3
People
16,390 planned
Started
30 Nov 2026
Primary completion
25 Nov 2032
Arms
RZV Group
Results
None posted
  1. 13 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Also known as RZV vaccine, Recombinant Herpes Zoster Vaccine (Shingrix), Recombinant zoster vaccine, Shingrix.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.